688029 南微医学
已收盘 11-04 15:00:00
资讯
新帖
简况
【浙商医药|孙建】南微医学Q3:海外高增持续,渠道拓展加速
杏林建研 · 11-04 23:08
【浙商医药|孙建】南微医学Q3:海外高增持续,渠道拓展加速
南微医学:累计回购约19万股
每日经济新闻 · 11-03 15:43
南微医学:累计回购约19万股
南微医学11月01日主力资金流入1247万元 连续3日加仓
市场透视 · 11-01
南微医学11月01日主力资金流入1247万元 连续3日加仓
南微医学:境内渠道库存见底 海外快速发展
国泰君安 · 11-01
南微医学:境内渠道库存见底 海外快速发展
东吴证券:给予南微医学买入评级
证券之星 · 10-31
东吴证券:给予南微医学买入评级
南微医学(688029)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 10-31
南微医学(688029)2024年三季报简析:营收净利润同比双双增长,盈利能力上升
国金证券:给予南微医学买入评级
证券之星 · 10-30
国金证券:给予南微医学买入评级
南微医学:海外渠道建设持续发力 可视化新品有序推进
中泰证券 · 10-30
南微医学:海外渠道建设持续发力 可视化新品有序推进
南微医学:3Q业绩同比稳定增长 海外发展顺利
华泰证券 · 10-30
南微医学:3Q业绩同比稳定增长 海外发展顺利
南微医学:2024年前三季度净利润约4.51亿元
每日经济新闻 · 10-29
南微医学:2024年前三季度净利润约4.51亿元
南微医学:拟收购欧洲内镜公司 增加公司海外业务布局
光大证券 · 10-28
南微医学:拟收购欧洲内镜公司 增加公司海外业务布局
南微医学10月24日遭主力抛售1012万元 环比增加332.48%
市场透视 · 10-24
南微医学10月24日遭主力抛售1012万元 环比增加332.48%
科技打头阵,如何低门槛布局科创板?
博时基金 · 10-22
科技打头阵,如何低门槛布局科创板?
南微医学大幅上涨 获融资净买入115万元
智选洞察 · 10-18
南微医学大幅上涨 获融资净买入115万元
10月14日南微医学发生1笔大宗交易 成交金额778.49万元
证券之星 · 10-14
10月14日南微医学发生1笔大宗交易 成交金额778.49万元
XD南微医大跌5.22% 5家券商给予增持建议
智选洞察 · 10-11
XD南微医大跌5.22% 5家券商给予增持建议
南微医学大跌5.01% 5家券商给予增持建议
智选洞察 · 10-09
南微医学大跌5.01% 5家券商给予增持建议
10月8日南微医学涨10.31%,工银精选平衡混合基金重仓该股
证券之星 · 10-08
10月8日南微医学涨10.31%,工银精选平衡混合基金重仓该股
南微医学涨10.31%,国金证券一个月前给出“买入”评级
证券之星 · 10-08
南微医学涨10.31%,国金证券一个月前给出“买入”评级
9月30日南微医学涨13.82%,工银精选平衡混合基金重仓该股
证券之星 · 09-30
9月30日南微医学涨13.82%,工银精选平衡混合基金重仓该股
加载更多
公司概况
公司名称:
南微医学科技股份有限公司
所属行业:
专用设备制造业
上市日期:
2019-07-22
主营业务:
南微医学科技股份有限公司的主营业务为微创医疗器械的研发、制造和销售。公司主要产品包括内镜诊疗器械、微波消融设备及耗材、一次性内镜。公司内镜诊疗器械主要包括活检类、止血和闭合类、EMR/ESD 类、扩张类、ERCP 类、EUS/EBUS类等六大类60多种上百个规格系列产品,微波消融主要包括微波消融仪和微波消融针系列产品。公司是我国内镜诊疗器械的主要制造商之一,是国内内镜诊疗器械、耗材细分领域中起步较早、创新能力强、产品线丰富、规模优势明显、迈向国际化的行业龙头企业。
发行价格:
52.45
{"stockData":{"symbol":"688029","market":"SH","secType":"STK","nameCN":"南微医学","latestPrice":70.85,"timestamp":1730703600000,"preClose":71.26,"halted":0,"volume":3813047,"delay":0,"floatShares":188000000,"shares":188000000,"eps":2.9306,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.41,"latestTime":"11-04 15:00:00","open":71.49,"high":72.88,"low":70.02,"amount":270000000,"amplitude":0.0401,"askPrice":70.85,"askSize":10,"bidPrice":70.84,"bidSize":9,"shortable":0,"etf":0,"ttmEps":2.9306,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1730770200000},"adr":0,"adjPreClose":71.26,"symbolType":"stock_kcb","openAndCloseTimeList":[[1730683800000,1730691000000],[1730696400000,1730703600000]],"highLimit":78.39,"lowLimit":64.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":187847422,"pbRate":3.57,"roa":"--","roe":"12.21%","epsLYR":2.59,"committee":-0.075949,"marketValue":13309000000,"floatMarketCap":13309000000,"peRate":24.175937,"changeRate":-0.0058,"turnoverRate":0.0203,"status":1,"afterMarket":{"amount":0,"volume":0,"close":70.85,"buyVolume":0,"sellVolume":0,"time":1730705639464,"indexStatus":"已收盘 11-04 15:30:00","preClose":71.26}},"requestUrl":"/m/hq/s/688029","defaultTab":"news","newsList":[{"id":"2480829035","title":"【浙商医药|孙建】南微医学Q3:海外高增持续,渠道拓展加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2480829035","media":"杏林建研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480829035?lang=zh_cn&edition=full","pubTime":"2024-11-04 23:08","pubTimestamp":1730732889,"startTime":"0","endTime":"0","summary":"另外,公司2024Q3已与CME公司签署并购合同,目前正在履行政府审批手续,争取在年底前完成交割。财务摘要表附录:三大报表预测值注意事项往期报告回顾点击报告标题直达↓南微医学24H1:海外收入亮眼,全年有望延续南微医学23A:国内稳步增长,海外高增持续南微医学23Q3:盈利能力恢复,海外市场加速固定布局工具条上设置固定宽高背景可以设置被包含可以完美对齐背景图和文字以及制作自己的模板团队成员","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104231015ab9ecfa8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241104231015ab9ecfa8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029","159938"],"gpt_icon":0},{"id":"2480356811","title":"南微医学:累计回购约19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480356811","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480356811?lang=zh_cn&edition=full","pubTime":"2024-11-03 15:43","pubTimestamp":1730619827,"startTime":"0","endTime":"0","summary":"每经AI快讯,南微医学 11月3日晚间发布公告称,截至2024年10月31日,公司已累计回购股份约19万股,占公司总股本的比例为0.1%,购买的最高价为62.74元/股、最低价为55.85元/股,已支付的总金额约为1109万元。2023年1至12月份,南微医学的营业收入构成为:医疗器械占比99.34%。南微医学的董事长是隆晓辉,男,65岁,学历背景为硕士;总经理是冷德嵘,男,61岁,学历背景为本科。截至发稿,南微医学市值为134亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103154429ab9a6a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103154429ab9a6a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2480739430","title":"南微医学11月01日主力资金流入1247万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2480739430","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480739430?lang=zh_cn&edition=full","pubTime":"2024-11-01 15:19","pubTimestamp":1730445581,"startTime":"0","endTime":"0","summary":"11月01日, 南微医学股价跌1.57%,报收71.26元,成交金额2.08亿元,换手率1.54%,振幅3.72%,量比0.94。南微医学今日主力资金净流入1247万元,连续3日净流入,上一交易日主力净流入955万元,今日环比增加30.58%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为30.77%,平均涨幅为2.12%。该股近5个交易日下跌1.04%,主力资金累计净流入4605万元;近20日主力资金累计净流出5557万元,其中净流出天数为14日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101155917ab90dab9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101155917ab90dab9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2480074516","title":"南微医学:境内渠道库存见底 海外快速发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2480074516","media":"国泰君安","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480074516?lang=zh_cn&edition=full","pubTime":"2024-11-01 00:00","pubTimestamp":1730390400,"startTime":"0","endTime":"0","summary":"国内增速放缓,海外保持较快增长。2024Q3 境内实现 3.23 亿元(-2%),河北联盟集采已经在河北、广西、云南等地落地执行,公司在集采地区止血夹销量明显提升,但由于主动降低渠道库存,报表增速承压。目前,国内经销商库存水平在3-3.5 个月左右,处于健康水平,去库结束后国内增速有望逐步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110116462595bda879&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110116462595bda879&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2479792876","title":"东吴证券:给予南微医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479792876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479792876?lang=zh_cn&edition=full","pubTime":"2024-10-31 08:30","pubTimestamp":1730334657,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对南微医学进行研究并发布了研究报告《2024三季报点评:业绩符合预期,内镜耗材出海布局领先》,本报告对南微医学给出买入评级,当前股价为70.2元。 单Q3季度毛利率保持稳定,期间费用控制良好。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级10家,增持评级3家;过去90天内机构目标均价为81.75。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100012021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688029"],"gpt_icon":0},{"id":"2479767148","title":"南微医学(688029)2024年三季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479767148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479767148?lang=zh_cn&edition=full","pubTime":"2024-10-31 06:22","pubTimestamp":1730326934,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期南微医学发布2024年三季报。截至本报告期末,公司营业总收入20.12亿元,同比上升15.3%,归母净利润4.51亿元,同比上升16.7%。按单季度数据看,第三季度营业总收入6.79亿元,同比上升13.44%,第三季度归母净利润1.41亿元,同比上升15.06%。本报告期南微医学盈利能力上升,毛利率同比增幅1.91%,净利率同比增幅82.81%。持有南微医学最多的基金为工银创新动力股票,目前规模为57.79亿元,最新净值1.159,较上一交易日下跌0.26%,近一年上涨12.16%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100007841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029"],"gpt_icon":0},{"id":"2479227502","title":"国金证券:给予南微医学买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479227502","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479227502?lang=zh_cn&edition=full","pubTime":"2024-10-30 16:52","pubTimestamp":1730278358,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司袁维,何冠洲近期对南微医学进行研究并发布了研究报告《三季度业绩稳定增长,海外市场布局进一步完善》,本报告对南微医学给出买入评级,当前股价为70.2元。营销及研发投入持续增加,巩固全球市场品牌力。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级10家,增持评级3家;过去90天内机构目标均价为81.75。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000029708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029"],"gpt_icon":0},{"id":"2479272860","title":"南微医学:海外渠道建设持续发力 可视化新品有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2479272860","media":"中泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479272860?lang=zh_cn&edition=full","pubTime":"2024-10-30 00:00","pubTimestamp":1730217600,"startTime":"0","endTime":"0","summary":"细化颗粒度销售管理效果显著,公司积极推进海外渠道建设。公司继续聚焦可视化关键项目,一次性内科胆道镜逐步进入欧、美、日等医院市场,同时公司正积极探索一次性内镜多元应用场景,创挖掘更多业务增长点。公司当前股价对应2024-2026年23、18、15 倍PE,考虑到公司所处微创诊疗器械行业国产化率低,一次性胆道镜等新产品上市有望推动业绩加速,维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103018253795bd8cbe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103018253795bd8cbe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2479244654","title":"南微医学:3Q业绩同比稳定增长 海外发展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2479244654","media":"华泰证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479244654?lang=zh_cn&edition=full","pubTime":"2024-10-30 00:00","pubTimestamp":1730217600,"startTime":"0","endTime":"0","summary":"我们认为公司产品结构优化、盈利能力提升,带动利润增速快于收入增速,我们看好后续海外收入快速增长,维持买入评级。3Q24 公司整体费用率同比基本稳定,毛利率同比提高9M24 销售/管理/研发/财务费用率分别为23.11%/12.38%/5.54%/-1.63%,同比+1.19/-0.59/-0.33/+1.99pct;3Q24 销售/管理/研发/财务费用率分别为23.86%/12.28%/6.19%/-1.33% , 同比+2.17/-0.09/+0.52/-2.91pct 。9M24/3Q24 毛利率分别为67.64%/67.06%,同比+3.60/+2.44pct,公司产品结构优化驱动盈利能力持续改善,毛利率同比提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410301431419f58e404&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410301431419f58e404&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2479285109","title":"南微医学:2024年前三季度净利润约4.51亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479285109","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479285109?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:25","pubTimestamp":1730208327,"startTime":"0","endTime":"0","summary":"每经AI快讯,南微医学 10月29日晚间发布三季度业绩公告称,2024年前三季度营收约20.12亿元,同比增加15.3%;归属于上市公司股东的净利润约4.51亿元,同比增加16.7%;基本每股收益2.41元,同比增加16.99%。南微医学的董事长是隆晓辉,男,65岁,学历背景为硕士;总经理是冷德嵘,男,61岁,学历背景为本科。截至发稿,南微医学市值为136亿元。道达号“个股趋势”提醒:1. 近30日内无机构对南微医学进行调研。一条消息引爆,巨无霸先正达旗下多股直冲涨停!","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029212647ab7f10e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029212647ab7f10e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029"],"gpt_icon":0},{"id":"2478126479","title":"南微医学:拟收购欧洲内镜公司 增加公司海外业务布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2478126479","media":"光大证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478126479?lang=zh_cn&edition=full","pubTime":"2024-10-28 00:00","pubTimestamp":1730044800,"startTime":"0","endTime":"0","summary":"事件:近期,公司公告拟使用自有资金不超过3672 万欧元通过全资子公司南微荷兰收购Creo Medical Group plc持有的Creo Medical S.L.U.51%股权。公司本次交易收购标的公司主要业务为内镜耗材销售,业务集中在西欧地区。我们预计本次收购有望提升公司在欧洲地区的产品销售能力,加速海外扩张,快速提升公司产品在欧洲市场的份额。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102814362195bd71d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102814362195bd71d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2477571524","title":"南微医学10月24日遭主力抛售1012万元 环比增加332.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477571524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477571524?lang=zh_cn&edition=full","pubTime":"2024-10-24 15:18","pubTimestamp":1729754338,"startTime":"0","endTime":"0","summary":"10月24日, 南微医学股价跌1.86%,报收70.00元,成交金额1.49亿元,换手率1.12%,振幅2.40%,量比0.77。南微医学今日主力资金净流出1012万元,上一交易日主力净流出234万元,今日环比增加332.48%。|10月24日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|N六九一二|33.74%|#|N苏州天脉|23.77%|#|欣灵电气|7.27%|#|银宝山新|4.85%|#|岭南股份|4.60%|#|特一药业|4.24%|#|经纬辉开|4.14%|#|华东数控|3.91%|#|文一科技|3.82%|#|跃岭股份|3.70%|南微医学所在的医疗器械行业,今日主力净流出7839万元,行业排名58/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024153327a1e61a44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241024153327a1e61a44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵,如何低门槛布局科创板?","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告,业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户,且满足交易风险评级要求,即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688326","688568","688779","688016","688005","688582","688690","688433","688208","688439","688192","688048","688343","000698","688520","688322","688248","688739","688083","688549","688327","688702","688029","688390","688161","688153","688063","688336","688050","688432","688347","688639","688366","688037","688198","688139","688007","159982","688352","688289","688276","688266","688172","688798","688686","688097","688110","688278","688333","688484","688002","688578","688567","688608","688177","688235","688348","688612","688019","688408","688166","688700","688141","688361","688536","688498","688409","688106","688062","688318","688088","688281","688232","688425","688575","688443","688516","688146","688213","688400","688027","688548","688387","688778","688617","688001","588030","688200","688055","688052","688107","688147","688017","688066","688105","688526","688032","688789","688772","688331","688006","688556","688717","688100"],"gpt_icon":0},{"id":"2476428876","title":"南微医学大幅上涨 获融资净买入115万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476428876","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476428876?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:16","pubTimestamp":1729228597,"startTime":"0","endTime":"0","summary":"10月18日,南微医学股价大幅上涨,截至13点16分,南微医学上涨5.15%,报70.85元/股,突破70元整数关口,成交1.77亿元,换手率1.37%,振幅5.97%。资金动向截止发稿,南微医学获得主力净流出888万元,其中超大单流出889万元,大单流入1万元。融资融券方面,南微医学10月17日获得融资净买入115万元,当日该股融资余额为2.39亿元,当较前一日增加0.49%;该股融券余额为237万元,融券余量为3.35万股,比上日增加8.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018133025a1e19a4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018133025a1e19a4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2475235364","title":"10月14日南微医学发生1笔大宗交易 成交金额778.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475235364","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475235364?lang=zh_cn&edition=full","pubTime":"2024-10-14 17:20","pubTimestamp":1728897653,"startTime":"0","endTime":"0","summary":"证券之星消息,10月14日南微医学发生大宗交易,交易数据如下:大宗交易成交价格69.82元,成交11.15万股,成交金额778.49万元,买方营业部为中国国际金融股份有限公司北京建国门外大街证券营业部,卖方营业部为平安证券股份有限公司深圳金田路证券营业部。近三个月该股共发生8笔大宗交易,合计成交7286.0手,折价成交5笔。截至2024年10月14日收盘,南微医学报收于69.82元,上涨1.13%,换手率1.62%,成交量3.04万手,成交额2.08亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400023658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2474873920","title":"XD南微医大跌5.22% 5家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2474873920","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474873920?lang=zh_cn&edition=full","pubTime":"2024-10-11 10:02","pubTimestamp":1728612171,"startTime":"0","endTime":"0","summary":"10月11日,XD南微医股价大幅下跌,截至10点02分,XD南微医下跌5.22%,报69.00元/股,失守70元整数关口,成交7802万元,换手率0.58%,振幅6.24%。此外,数据统计显示,近半年内5家券商给予增持建议,17家券商给予买入建议。资金动向截止发稿,XD南微医获得主力净流出35万元,其中超大单流入115万元,大单流出150万元。最新财报显示,今年中报,XD南微医实现营业收入13.34亿元,同比增长16.28%,净利润为3.10亿元,同比增长17.47%,基本每股收益为1.66元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011110854a1dfdcab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241011110854a1dfdcab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2474266569","title":"南微医学大跌5.01% 5家券商给予增持建议","url":"https://stock-news.laohu8.com/highlight/detail?id=2474266569","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474266569?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:30","pubTimestamp":1728437402,"startTime":"0","endTime":"0","summary":"10月09日,南微医学股价大幅下跌,截至09点30分,南微医学下跌5.01%,报80.27元/股,成交474万元,换手率0.03%,振幅0.04%。资金动向截止发稿,南微医学获得主力净流出341万元,其中超大单流入350万元,大单流出690万元。主营业务及业绩南微医学公司主营业务为微创医疗器械研发、制造和销售。最新财报显示,今年中报,南微医学实现营业收入13.34亿元,同比增长16.28%,净利润为3.10亿元,同比增长17.47%,基本每股收益为1.66元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009123906a1df458e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241009123906a1df458e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688029","BK0251"],"gpt_icon":0},{"id":"2473435164","title":"10月8日南微医学涨10.31%,工银精选平衡混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2473435164","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473435164?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:03","pubTimestamp":1728378212,"startTime":"0","endTime":"0","summary":"证券之星消息,10月8日南微医学涨10.31%创60日新高,收盘报84.5元,换手率5.13%,成交量9.63万手,成交额8.05亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为工银精选平衡混合。杨鑫鑫在任的基金产品包括:工银创新动力股票,管理时间为2019年2月28日至今,期间收益率为125.9%;工银精选平衡混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800024941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688029"],"gpt_icon":0},{"id":"2473436344","title":"南微医学涨10.31%,国金证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2473436344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2473436344?lang=zh_cn&edition=full","pubTime":"2024-10-08 17:03","pubTimestamp":1728378206,"startTime":"0","endTime":"0","summary":"今日南微医学涨10.31%,收盘报84.5元。2024年8月23日,国金证券研究员袁维,何冠洲发布了对南微医学的研报《国际市场销售快速增长,业务毛利率显著提升》,该研报对南微医学给出“买入”评级。研报中预计2024-2026年公司归母净利润分别为6.11、7.89、9.70亿元,同比增长26%、29%、23%,现价对应PE为18、14、11倍,维持“买入”评级。此外,中泰证券研究员祝嘉琦,谢木青,于佳喜,东吴证券研究员朱国广近期也对该股发布了研报,同样给出“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100800024939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029"],"gpt_icon":0},{"id":"2471787156","title":"9月30日南微医学涨13.82%,工银精选平衡混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2471787156","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2471787156?lang=zh_cn&edition=full","pubTime":"2024-09-30 17:34","pubTimestamp":1727688859,"startTime":"0","endTime":"0","summary":"证券之星消息,9月30日南微医学涨13.82%创60日新高,收盘报76.6元,换手率3.55%,成交量6.66万手,成交额4.85亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共19家,其中持有数量最多的公募基金为工银精选平衡混合。杨鑫鑫在任的基金产品包括:工银创新动力股票,管理时间为2019年2月28日至今,期间收益率为109.71%;工银精选平衡混合的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024093000030606.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688029","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-07-22","address":"江苏省南京市浦口区高新开发区高科三路10号","stockEarnings":[{"period":"1week","weight":-0.0514},{"period":"1month","weight":-0.0687},{"period":"3month","weight":0.16},{"period":"6month","weight":-0.0221},{"period":"1year","weight":-0.1665},{"period":"ytd","weight":-0.2514}],"companyName":"南微医学科技股份有限公司","boardCode":"AI0035","perCapita":"18142股","boardName":"专用设备制造业","registeredCapital":"18784万元","compareEarnings":[{"period":"1week","weight":-0.0036},{"period":"1month","weight":-0.0079},{"period":"3month","weight":0.1545},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.0922},{"period":"ytd","weight":0.1127}],"survey":" 南微医学科技股份有限公司的主营业务为微创医疗器械的研发、制造和销售。公司主要产品包括内镜诊疗器械、微波消融设备及耗材、一次性内镜。公司内镜诊疗器械主要包括活检类、止血和闭合类、EMR/ESD 类、扩张类、ERCP 类、EUS/EBUS类等六大类60多种上百个规格系列产品,微波消融主要包括微波消融仪和微波消融针系列产品。公司是我国内镜诊疗器械的主要制造商之一,是国内内镜诊疗器械、耗材细分领域中起步较早、创新能力强、产品线丰富、规模优势明显、迈向国际化的行业龙头企业。","serverTime":1730755444949,"listedPrice":52.45,"stockholders":"10354人(较上一季度增加3.13%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"南微医学(688029)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供南微医学(688029)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"南微医学,688029,南微医学股票,南微医学股票老虎,南微医学股票老虎国际,南微医学行情,南微医学股票行情,南微医学股价,南微医学股市,南微医学股票价格,南微医学股票交易,南微医学股票购买,南微医学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"南微医学(688029)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供南微医学(688029)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}